Denovo Biopharma Inks Licensing Deal With Chuang Yi for DB104 in Taiwan
CompanyDeals

Denovo Biopharma Inks Licensing Deal With Chuang Yi for DB104 in Taiwan

Hengrui Pharmaceuticals Wins NMPA Approval for Six Novel Solid Tumor Drugs
CompanyDrug

Hengrui Pharmaceuticals Wins NMPA Approval for Six Novel Solid Tumor Drugs

Gan & Lee Pharmaceuticals Presents Phase II Results of GZR18 and GZR4 at ADA Scientific Sessions
CompanyDrug

Gan & Lee Pharmaceuticals Presents Phase II Results of GZR18 and GZR4 at ADA Scientific Sessions

EMA Panel Recommends Bio-Thera's Usymro for Autoimmune Diseases
CompanyDrug

EMA Panel Recommends Bio-Thera’s Usymro for Autoimmune Diseases

J&J's Darzalex SC Recommended by CHMP for High-Risk Smoldering Multiple Myeloma
CompanyDrug

J&J’s Darzalex SC Recommended by CHMP for High-Risk Smoldering Multiple Myeloma

Eli Lilly's Efsitora Meets Key Endpoints in Phase III Trials for Type 2 Diabetes
CompanyDrug

Eli Lilly’s Efsitora Meets Key Endpoints in Phase III Trials for Type 2 Diabetes

Johnson & Johnson's Imbruvica Secures CHMP Recommendation for Expanded MCL Use
CompanyDrug

Johnson & Johnson’s Imbruvica Secures CHMP Recommendation for Expanded MCL Use

Bayer's Nubeqa Receives Positive CHMP Opinion for mHSPC Treatment
CompanyDrug

Bayer’s Nubeqa Receives Positive CHMP Opinion for mHSPC Treatment

Boao Lecheng Partners with China National Center for Neurological Diseases to Establish Translational Center
CompanyDeals

Boao Lecheng Partners with China National Center for Neurological Diseases to Establish Translational Center

Sichuan Huiyu's CDCP1-Targeted ADC HY0001a Gets NMPA Clinical Trial Approval
CompanyDrug

Sichuan Huiyu’s CDCP1-Targeted ADC HY0001a Gets NMPA Clinical Trial Approval

Changshan Biochemical Receives NMPA Clearance for Albenatide in Weight Loss Trials
CompanyDrug

Changshan Biochemical Receives NMPA Clearance for Albenatide in Weight Loss Trials

ImmuneOnco Receives NMPA Approval for IMC-003/IMM72 in Pulmonary Arterial Hypertension Trial
CompanyDrug

ImmuneOnco Receives NMPA Approval for IMC-003/IMM72 in Pulmonary Arterial Hypertension Trial